These past two days, small-cap biotech stocks have gone completely crazy, with Biodexa and Enveric taking turns to skyrocket, and iBio following suit—last year was a total loss, but the real action happened when we were on the sidelines. I was just researching Oscar Health, but insurtech is all red while medtech has become the new darling of capital. Market sentiment changes in a flash, and it’s still a case of 'others make money while I’m left holding the bag.' It’s both funny and frustrating—just a reminder that biotech is always a rollercoaster, and missing one ride feels like falling behind for the whole year…